On Thursday, Cantor Fitzgerald reiterated its Overweight rating on shares of ORIC Pharmaceuticals (NASDAQ: ORIC), currently trading at $5.97, following the company’s announcement of promising ...

Cantor Fitzgerald analyst Prakhar Agrawal commented on the results, stating, "Overall, a solid update by ORIC with not much to nitpick on efficacy/safety." Agrawal reiterated an Overweight rating on ...

Shares of ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) jumped 20% following the release of early data from its ongoing Phase 1b ...

On Thursday, Cantor Fitzgerald reiterated its Overweight rating on shares of ORIC Pharmaceuticals (NASDAQ: ORIC), currently trading at $5.97, following the company’s announcement of promising Phase 1 ...

Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The leading factor in the rating is the parent firm's five-year risk-adjusted success ratio of 74%.

Cantor Fitzgerald International Eq Fund earns an Above Average Process Pillar rating. The leading factor in the rating is the parent firm's five-year risk-adjusted success ratio of 74%.

The Fund seeks long-term growth of capital. Under normal circumstances, the Fund will invest at least 80% of its net assets in equity securities. Beginning with a universe of the largest ...

Explore ORIC Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ORIC. ORIC: Working with Two Pharma Giants, Analysts See +100% Upside ORIC ...